NeuroClues is a European MedTech company developing AI-powered neurological diagnostics. The company has developed a CE-marked medical device that extracts objective neurological biomarkers from eye movements, enabling faster and more accurate diagnosis of neurodegenerative diseases, and is already deployed across seven European countries with strong clinical adoption.

The Series A round, led by Teampact Ventures, White Fund and the EIC Fund, with participation from existing investors, will support the acceleration of commercial deployment across Europe and prepare the company’s expansion into the United States.

Through this transaction, NeuroClues secures the resources required to scale one of the fastest-growing neurotech platforms in Europe, leveraging both strong clinical traction and a differentiated AI-driven technology.

By supporting NeuroClues in this strategic financing, Allyum further demonstrates its expertise in advising high-growth companies in complex fundraising transactions, particularly in innovative and technology-driven sectors.